文献速递关节外科创伤骨科

入院时淋巴细胞与C反应蛋白比值可预测无菌性翻修全髋关节置换术后90天不良结局

Admission Lymphocyte-to-C-Reactive Protein Ratio Predicts 90-Day Adverse Outcomes Following Aseptic Revision Total Hip Arthroplasty.
PubMed 文献 · J Arthroplasty · 2025-11-07

该回顾性队列研究纳入2010至2022年在一家三级关节置换中心接受无菌性翻修全髋关节置换术的5596例患者,评估入院时淋巴细胞与C反应蛋白比值(LCR)对术后90天不良事件的预测价值。结果显示,716例(12.8%)发生术后不良事件,入院LCR降低与主要并发症、次要并发症、非计划再入院及死亡风险增加相关,LCR截断值2.71时曲线下面积0.93。

要点

  • 入院LCR降低与主要并发症风险增加相关(OR 22.6,95%CI 14.45-35.36,P<0.001)。
  • LCR预测不良结局的最佳截断值为2.71,曲线下面积0.93,灵敏度87.1%,特异度95.7%。
  • 无菌性翻修全髋关节置换术后90天不良事件发生率为12.8%(716/5596)。

核心结论

  • 入院LCR可作为预测无菌性翻修全髋关节置换术后90天不良事件的有效且经济实惠的生物标志物。
  • 术前评估LCR可显著增强风险分层,为临床决策提供信息并优化术后护理。
  • 需要进一步的前瞻性研究来验证这些发现并阐明潜在的病理生理机制。

研究设计与样本

  • 回顾性队列分析,纳入2010至2022年在一家三级关节置换中心接受无菌性翻修全髋关节置换术的5596例患者。
  • 收集患者人口学特征、临床参数和围手术期数据,分析术后90天内不良结局(包括主要和次要并发症、非计划再入院及死亡)。
  • 采用逻辑回归分析评估术前LCR及其他潜在危险因素的预测价值,并使用受试者工作特征曲线分析确定最佳LCR截断值。
  • 证据等级为III级。

主要发现

  • 共有716例患者(12.8%)发生术后不良事件,这些患者的入院LCR显著低于对照组。
  • 多因素分析显示,术前LCR降低与主要并发症风险增加强烈相关(OR 22.6,95%CI 14.45-35.36,P<0.001)。
  • 术前LCR降低与次要并发症风险增加相关(OR 1.89,95%CI 1.39-2.23,P=0.002)。
  • 术前LCR降低与非计划再入院风险增加相关(OR 2.14,95%CI 1.49-3.14,P<0.001)。
  • 术前LCR降低与死亡风险增加相关(OR 4.89,95%CI 3.74-6.58,P<0.001)。

关键数值与推荐

  • 主要并发症:OR 22.6,95%CI 14.45-35.36,P<0.001。
  • 次要并发症:OR 1.89,95%CI 1.39-2.23,P=0.002。
  • 非计划再入院:OR 2.14,95%CI 1.49-3.14,P<0.001。
  • 死亡:OR 4.89,95%CI 3.74-6.58,P<0.001。
  • LCR截断值2.71,曲线下面积0.93,灵敏度87.1%,特异度95.7%。

临床怎么用

  • 术前评估LCR可显著增强风险分层,为临床决策提供信息并优化术后护理。
  • 需要进一步的前瞻性研究来验证这些发现并阐明潜在的病理生理机制。

局限性

  • 需要进一步的前瞻性研究来验证这些发现并阐明潜在的病理生理机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Revision total hip arthroplasty (rTHA) is linked to a greater risk of adverse postoperative outcomes in comparison to primary THA, owing to heightened surgical complexity and the burden of patient comorbidities. Consequently, there is an imperative need for an easily accessible predictor to facilitate preoperative risk stratification before rTHA. This study was conducted to evaluate the predictive utility of the admission lymphocyte-to-C-reactive protein ratio (LCR) concerning adverse events within 90 days postoperatively following aseptic rTHA. METHODS: A retrospective cohort analysis was conducted involving 5,596 patients who underwent aseptic rTHA from 2010 to 2022 at a tertiary arthroplasty center. Patient demographics, clinical parameters, and perioperative data were collected. Adverse outcomes within 90 days postoperatively, including major and minor complications, unplanned readmissions, and mortality, were analyzed. Logistic regression analysis was performed to estimate the predictive value of preoperative LCR in conjunction with other potential risk factors, whereas receiver operating characteristic curve analysis was used to establish the most appropriate LCR cutoff values. RESULTS: A total of 716 patients (12.8%) experienced postoperative adverse events. The admission LCR was significantly lower among these patients compared to controls. Multivariate analysis revealed that a reduced preoperative LCR was strongly associated with an increased risk of major complications (odds ratio [OR] 22.6, 95% confidence interval [CI] 14.45 to 35.36; P < 0.001), minor complications (OR 1.89, 95% CI 1.39 to 2.23, P = 0.002), unplanned readmissions (OR 2.14, 95% CI 1.49 to 3.14, P < 0.001), and mortality (OR 4.89, 95% CI 3.74 to 6.58, P < 0.001). The receiver operating characteristic analysis identified an optimal LCR cutoff value of 2.71, with an area under the curve of 0.93, sensitivity of 87.1%, and specificity of 95.7% for predicting adverse outcomes. CONCLUSIONS: Admission LCR serves as a potent, cost-effective biomarker for predicting 90-day adverse events following aseptic rTHA. Preoperative assessment of LCR can significantly enhance risk stratification, informing clinical decisions and optimizing postoperative care. Further prospective research is necessary to validate these findings and elucidate the underlying pathophysiological mechanisms. LEVEL OF EVIDENCE: Level III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Karlidag T, Zanna L, Mundhe A, et al. Admission Lymphocyte-to-C-Reactive Protein Ratio Predicts 90-Day Adverse Outcomes Following Aseptic Revision Total Hip Arthroplasty. J Arthroplasty. 2025. PMID: 41207340. doi:10.1016/j.arth.2025.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。